The association of MR-proANP and MR-proADM as well as MR-proANP tertiles and MR-proADM tertiles and furthermore for patients with high risk (both MR-proANP and MR-proADM in the highest tertile) with different endpoints using multiple Cox-proportional hazards models.

MR-proANP, mid-regional pro-atrial natriuretic peptide; MR-proADM, mid-regional pro-adrenomedullin.
Model 1: adjusted for age, sex, previous CVD**, diabetes mellitus, time-dependent type of renal replacement therapy.
Model 2: adjusted as in model 1 and additionally for albumin, CRP, current smoking, native fistula, echocardiography (ejection fraction ≤60% and >60%).
aFor MR-proANP and MR-proADM 1 standard deviation (SD) increment was 524 pmol/L and 1.29 nmol/L, respectively. One SD was taken as the unit of increment for each of the continuous outcome variables to ensure comparability of Hazard Ratios.
bAdjusted for age, sex, previous CVD**, diabetes mellitus, time-dependent type of renal replacement therapy.
*CV mortality: myocardial infarction, heart failure, sudden cardiac death, ischemic stroke, hemorrhagic stroke.
**CVD: myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, angiographically-proven coronary stenosis ≥50%, ischemic or hemorrhagic cerebral infarction, transient ischemic attack, carotid stenosis and carotid endarterectomy.
***PAD: significant ultrasound- or angiographically-proven vascular stenosis, percutaneous transluminal angioplasty, peripheral bypass, amputation.